Us Turns Down Glaxo Plea for Speedy Review of Cancer Drug
Evening Standard - London › June 01, 2007
Linked as:
Summary
DRUGS giant GlaxoSmithKline has hit another setback with news that its Cervarix cervical cancer vaccine will not get a priority review from the US Food and Drug Administration.
The regulator has the power to speed up product reviews if there is an urgent need or the drug represents significant improvements over current therapies.See the full content of this document
Extract
Us Turns Down Glaxo Plea for Speedy Review of Cancer Drug
But Glaxo spokeswoman Liad Diamond said it...
See the full content of this document
Sponsored links
